PCBL Chemical Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹12.5K Cr
PCBL expects significant growth in both volume and value over the next 1-2 years, driven by increasing Indian demand and expansion in the U.S. PCBL expects significant growth in both volume and value for the carbon black business over the next 1-2 years, driven by rising domestic demand and international expansion in the U.S.
From PCBL Chemical's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹320
Market Cap
₹12.5K Cr
P/E Ratio
47.2
Revenue Rank
Margin Rank
How does PCBL Chemical rank in Chemicals & Petrochemicals?
Compare PCBL Chemical against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
PCBL Chemical — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹40 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →PCBL expects significant growth in both volume and value over the next 1-2 years, driven by increasing Indian demand and expansion in the U.S. and Europe markets.
- →Strong growth in specialty carbon blacks, with new product launches enhancing the portfolio.
- →Despite short-term volume timing issues, full-year high single-digit volume growth is anticipated.
- →Aquapharm Chemicals aims for revenue and margin growth through launching commercial phosphonates products, expanding green chelates, and geographic penetration in Europe and Latin America.
- →Oil and gas segment is expected to be volatile short-term but stabilize later, supporting growth.
- →Domestic carbon black sales grew 15% YoY while international volumes are expected to scale up as export logistics normalize.
- →New contracts in international markets are in advanced negotiation, indicating future volume growth.
- →Cost efficiencies and pricing discipline focus to sustain margins alongside volume growth.
📈 Profitability & Margins
Rank 3- →PCBL expects significant growth in both volume and value for the carbon black business over the next 1-2 years, driven by rising domestic demand and international expansion in the U.S. and Europe.
- →Specialty carbon black products show positive outlook with growing customer acceptance and new product launches.
- →Despite some short-term volatility, long-term margin improvement is targeted through pricing discipline and focusing on higher-margin volumes.
- →Aquapharm segment anticipates growth from commercialization of green chelates and phosphonates products, though oil & gas division may face near-term volatility before stabilizing.
- →EBITDA per ton guidance for carbon black is around INR16,500-17,000 for FY27, representing a 14-15% improvement over FY26.
- →Overall EBITDA and profits are expected to grow, supported by cost efficiency programs and moderate capex investments (~INR300 crores).
- →Management remains positive on achieving sustainable earnings growth with expanded capacities, new product introductions, and international market penetration.
🏗️ Capital Expenditure Plans
Yes- →FY27 greenfield expansion capex will be limited, with major expenses expected next year (refer to Andhra facility licensing progress).
- →Around INR100 crores of strategic capex planned in FY27, mainly efficiency and cost optimization projects.
- →Overall FY27 capex outlook: ~INR300 crores, plus/minus INR50 crores, mostly maintenance and productivity enhancements; greenfield expansion largely completed.
- →Coal tar distillation project progressing well; business plan and equipment evaluation underway with capex approval targeted within the quarter.
- →Focus on volume and value growth in carbon black, specialty chemicals, and new product developments driving future investments.
- →Aquapharm growth initiatives include capacity discussions for green chelates and product commercializations; oil and gas expansions planned regionally (U.S., Latin America, Europe).
- →Nanovace pilot plant operational; sustained long-term investment in battery materials and specialty chemicals R&D ongoing.
💰 Fundraising & Capital Structure
No information- →The call transcript does not mention any current or planned fundraising through debt or equity.
- →Management discusses capex and investments, including strategic capex of about INR100 crores this year and a total capex outlook around INR300 crores (plus/minus INR50 crores), mostly funded internally.
- →No explicit reference is made to raising funds via equity or debt in the near term.
- →Focus remains on operational investments and project approvals, such as coal tar distillation and battery materials expansion.
- →Any future funding plans, if any, have not been disclosed in this call.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were PCBL Chemical Q1 FY27 results?
PCBL expects significant growth in both volume and value over the next 1-2 years, driven by increasing Indian demand and expansion in the U.S. PCBL expects significant growth in both volume and value for the carbon black business over the next 1-2 years, driven by rising domestic demand and international expansion in the U.S.
What is PCBL Chemical share price analysis?
PCBL Chemical currently shows a below-average growth signal. The stock trades at a P/E of 47.2 with a market cap of ₹12,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is PCBL Chemical planning capital expenditure?
FY27 greenfield expansion capex will be limited, with major expenses expected next year (refer to Andhra facility licensing progress).
Keep PCBL Chemical on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.